John W Steinke1, Monica G Lawrence2. 1. Asthma and Allergic Disease Center, Carter Immunology Center, University of Virginia Health Systems, Charlottesville, Virginia. Electronic address: js3ch@virginia.edu. 2. Asthma and Allergic Disease Center, Carter Immunology Center, University of Virginia Health Systems, Charlottesville, Virginia.
Abstract
OBJECTIVE: This review discusses the current state of immunotherapy and how the CD4 T-cell response is pivotal in altering the allergic response. DATA SOURCES: PubMed literature review. STUDY SELECTIONS: Articles pertaining to subcutaneous, sublingual, and oral immunotherapies, with specific emphasis on those describing the T-cell response. RESULTS: Although many drugs are available that help ameliorate allergic symptoms, the only intervention that has proved to provide long-term benefit and modulation of disease is immunotherapy. Many routes of immunotherapy are being pursued, including subcutaneous, sublingual, and oral immunotherapies; however, subcutaneous immunotherapy has the historical record of leading to immune changes that alter the immune response at subsequent allergen exposure. These changes are mediated by the induction of peripherally derived T-regulatory cells and appear to occur only after high-dose therapy for 3 to 5 years. Newer methods of sublingual and oral immunotherapies are currently being investigated, but their efficacy is not yet on par with subcutaneous immunotherapy. CONCLUSION: The primary cells ultimately responsible for successful immunomodulation are CD4 T cells, specifically peripherally derived T-regulatory cells.
OBJECTIVE: This review discusses the current state of immunotherapy and how the CD4 T-cell response is pivotal in altering the allergic response. DATA SOURCES: PubMed literature review. STUDY SELECTIONS: Articles pertaining to subcutaneous, sublingual, and oral immunotherapies, with specific emphasis on those describing the T-cell response. RESULTS: Although many drugs are available that help ameliorate allergic symptoms, the only intervention that has proved to provide long-term benefit and modulation of disease is immunotherapy. Many routes of immunotherapy are being pursued, including subcutaneous, sublingual, and oral immunotherapies; however, subcutaneous immunotherapy has the historical record of leading to immune changes that alter the immune response at subsequent allergen exposure. These changes are mediated by the induction of peripherally derived T-regulatory cells and appear to occur only after high-dose therapy for 3 to 5 years. Newer methods of sublingual and oral immunotherapies are currently being investigated, but their efficacy is not yet on par with subcutaneous immunotherapy. CONCLUSION: The primary cells ultimately responsible for successful immunomodulation are CD4 T cells, specifically peripherally derived T-regulatory cells.
Authors: Danilo Di Bona; Antonella Plaia; Maria Stefania Leto-Barone; Simona La Piana; Gabriele Di Lorenzo Journal: J Allergy Clin Immunol Date: 2012-09-27 Impact factor: 10.793
Authors: Stacy J Chin; Brian P Vickery; Michael D Kulis; Edwin H Kim; Pooja Varshney; Pamela Steele; Janet Kamilaris; Anne M Hiegel; Suzanna K Carlisle; P Brian Smith; Amy M Scurlock; Stacie M Jones; A Wesley Burks Journal: J Allergy Clin Immunol Date: 2013-03-25 Impact factor: 10.793
Authors: Abul K Abbas; Christophe Benoist; Jeffrey A Bluestone; Daniel J Campbell; Sankar Ghosh; Shohei Hori; Shuiping Jiang; Vijay K Kuchroo; Diane Mathis; Maria Grazia Roncarolo; Alexander Rudensky; Shimon Sakaguchi; Ethan M Shevach; Dario A A Vignali; Steve F Ziegler Journal: Nat Immunol Date: 2013-04 Impact factor: 25.606
Authors: John F Ryan; Rachel Hovde; Jacob Glanville; Shu-Chen Lyu; Xuhuai Ji; Sheena Gupta; Robert J Tibshirani; David C Jay; Scott D Boyd; R Sharon Chinthrajah; Mark M Davis; Stephen J Galli; Holden T Maecker; Kari C Nadeau Journal: Proc Natl Acad Sci U S A Date: 2016-01-25 Impact factor: 11.205
Authors: Matti Adam; Nigel Geoffrey Kooreman; Ann Jagger; Markus U Wagenhäuser; Dennis Mehrkens; Yongming Wang; Yosuke Kayama; Kensuke Toyama; Uwe Raaz; Isabel N Schellinger; Lars Maegdefessel; Joshua M Spin; Jaap F Hamming; Paul H A Quax; Stephan Baldus; Joseph C Wu; Philip S Tsao Journal: Arterioscler Thromb Vasc Biol Date: 2018-08 Impact factor: 8.311